Strategic leadership Covalon has recently appointed independent director Murray Miller and appointed Abe Schwartz as board chair, signaling governance refinement and potential emphasis on strategic growth and oversight which can open doors for strategic partnerships and larger deals.

Boardroom engagement Active participation in microcap showcases and industry events (Planet MicroCap, Planet MicroCap TORONTO 2025; Planet MicroCap VEGAS 2025) presents multiple opportunities to connect with investors and potential channel partners looking for innovative wound care and vascular access solutions.

Growth momentum Revenue range of 100M to 250M and recent recognition as a TSX Venture Exchange Top 50 Company indicate solid market traction and credibility, suggesting potential for upsell on high-margin consumables, advanced wound care products, and bundled clinical solutions.

Operat ing scale Leadership promotion of Kim Crooks to COO and ongoing product initiatives such as VALGuard research point to expanding operational capacity and R&D which could benefit by partnerships on manufacturing efficiencies, supply agreements, and scaled distribution.

Healthcare focus Specialization in wound care, vascular access, and surgical consumables with a mission to reduce HAIs and protect skin aligns with demand for infection-preventive technologies and skin-protection products, offering cross-sell opportunities to hospitals, clinics, and long-term care facilities.